Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 6 for:    CytoSorbents
Previous Study | Return to List | Next Study

Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal (PACIFIC)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified March 2017 by Technische Universität München
Sponsor:
Collaborator:
CytoSorbents Europe GmbH
Information provided by (Responsible Party):
Wolfgang Huber, Technische Universität München
ClinicalTrials.gov Identifier:
NCT03082469
First received: January 13, 2017
Last updated: March 10, 2017
Last verified: March 2017
  Purpose

Severe acute pancreatitis (SAP) has a mortality of up to 42%. The outcome of SAP is related to the development of SIRS and consecutive organ failures. Due to the lack of a causative therapy except the removal of bile duct stones, therapy is predominantly symptomatic.

With regard to a marked inflammatory response ("cytokine storm") during the early phase of SAP extracorporeal cytokine removal is a promising therapeutic approach.

This prospective case control study investigates the impact of early extracorporeal cytokine adsorption with the CytoSorb®-device on haemodynamics (primary endpoint) and several secondary outcomes.


Condition Intervention Phase
Pancreatitis, Acute
SIRS
Device: CytoSorb
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description:
Inflammatory cytokine removal by Cyto Sorb treatment
Masking: No masking
Primary Purpose: Treatment
Official Title: Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal: A Prospective Study.

Resource links provided by NLM:


Further study details as provided by Technische Universität München:

Primary Outcome Measures:
  • Haemodynamics [ Time Frame: Within 48h after the onset of CytoSorb treatment ]
    Improvement of the vasopressor dependency index >=20%. (Improvement of cardiac power index >=20% in case of no vasopressor use at baseline)


Secondary Outcome Measures:
  • Mortality-1 [ Time Frame: 28 days from inclusion into the study ]
    28-days-mortality

  • Mortality-2 [ Time Frame: From admission to the ICU until discharge or transfer from the ICU (up to one year) ]
    ICU-mortality

  • Mortality-3 [ Time Frame: From admission to discharge from the hospital (up to one year) ]
    Hospital-mortality

  • Inflammation [ Time Frame: Within 48h after the onset of CytoSorb treatment ]
    IL-6, CRP and PCT-values levels compared to before CytoSorb treatment

  • Respiratory outcome [ Time Frame: Within 28 days after the onset of CytoSorb treatment ]
    Ventilator-free days

  • Renal function and its Change over time [ Time Frame: Within 28 days after the onset of CytoSorb treatment ]
    Daily classification according to KDIGO; comparison vs. before Cyto Sorb treatment


Estimated Enrollment: 30
Anticipated Study Start Date: March 15, 2017
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: CytoSorb
CytoSorb therapy for 48h
Device: CytoSorb
Two consecutive 24h treatments with the CytoSorb-device
No Intervention: Matched controls
60 matched controls with SAP and transpulmonary thermodilution monitoring

Detailed Description:

Severe acute pancreatitis (SAP) has a mortality of up to 42%. The outcome of SAP is related to the development of SIRS and consecutive organ failures. Due to the lack of a causative therapy except the removal of bile duct stones, therapy is predominantly symptomatic.

Severity and mortality are associated to an early systemic inflammatory response syndrome (SIRS) and to septic complications at a later stage of disease.

With regard to a marked inflammatory response ("cytokine storm") during the early phase of SAP extracorporeal cytokine removal is a promising therapeutic approach.

This prospective case control study investigates the impact of early extracorporeal cytokine adsorption with the CytoSorb® device on haemodynamics (primary endpoint) and several secondary outcomes.

Patients with high probability of SAP (APACHE-II-score ≥10) are eligible for 7 days after the onset of pain.

The patients will be treated for 48h with two consecutive 24h sessions of cytokine absorption with the CytoSorb®-device.

All patients will be under haemodynamic Monitoring with transpulmonary thermodilution The primary endpoint is defined as an improvement of the vasopressor dependency index of ≥20% (if no vasoactive drugs are used at baseline, the cardiac power index cardiac power index (CPI) will be used as primary endpoint).

The outcome analysis will be based on comparison of the incidence of the primary endpoint in 30 Intervention patients compared to 60 matched controls.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Proven acute pancreatitis:

    • typical pain
    • at least 3-fold increase in serum lipase
    • onset of pain within 7 days before inclusion AND
  • APACHE-II ≥10 AND
  • ≥1 criterion of "severe sepsis" AND
  • Haemodynamic monitoring with transpulmonary thermodilution AND
  • ≥ 1 marker of poor prognosis of acute pancreatitis:

    • Haematocrit > 44% (men), >40% (women)
    • Blood glucose > 125 mg/dL
    • C-reactive protein (CRP) > 10mg/dL
    • Computed tomography score category C-E
    • Age >55 years
    • Leukocytes >16 G/L
    • Glutamate oxaloacetate transferase (GOT) >250 U/L
    • Lactate dehydrogenase (LDH) >350 U/L
    • Calcium <2,0mmol/L

Exclusion Criteria:

  • pregnancy
  • lack of informed consent of patient or representative
  • pre-existing disease with life expectancy <3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03082469

Contacts
Contact: Wolfgang Huber, Professor ++49-89-4140-5214 Wolfgang.Huber@tum.de
Contact: Tobias Lahmer, MD ++49-89-4140-9345 Tobias.Lahmer@mri.tum.de

Sponsors and Collaborators
Technische Universität München
CytoSorbents Europe GmbH
Investigators
Principal Investigator: Wolfgang Huber, Professor II. Medizinische Klinik; Klinikum rechts der Isar; Technische Universität München
  More Information

Responsible Party: Wolfgang Huber, Professor Dr. Wolfgang Huber, Technische Universität München
ClinicalTrials.gov Identifier: NCT03082469     History of Changes
Other Study ID Numbers: PACIFIC 10-2015
Study First Received: January 13, 2017
Last Updated: March 10, 2017
Individual Participant Data  
Plan to Share IPD: No
Plan Description: n.a.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Technische Universität München:
Severe acute pancreatitis
Haemodynamic monitoring
Cytokine removal
Vasopressor dependency index

Additional relevant MeSH terms:
Pancreatitis
Pancreatic Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on May 24, 2017